Remarkably, the distinct distribution patterns of α-syn/tau co-pathology in various disorders — co-pathology in the limbic and olfactory regions in AD versus co-pathology in the substantia nigra and brainstem in PD — highlight their heterogeneity and present challenges for differential diagnosis and development of targeted immunotherapies [72, 73]. The gene discussed is MAPT; the disease is Parkinson disease.